New York, New York (PRWEB) April 28, 2015
Dr. Harton will be responsible for Progyny’s commercial operations including sales, marketing, and customer service operations across the products of Fertility Authority.com, EggBanxx, IVFAdvantage and The Eeva Test, the first and only FDA-cleared test to use time lapse imaging combined with their proprietary algorithm to aid in embryo selection during IVF.
Dr. Harton has joined Progyny following a long career in the field of Reproductive Sciences, including both laboratory management and IVF practice management posts. In addition, Dr. Harton has spent the last 3 years on the commercial side of the IVF business building up companies that create and supply molecular solutions for preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS), as well as other aspects of the reproductive genetics field.
As a well-respected member of the IVF and PGD community, and author on more than 50 peer-reviewed scientific articles, abstracts and book chapters, Dr. Gary Harton brings a wealth of expertise to the role. Commenting on this appointment, CEO of Progyny, Gina Bartasi, says, “We are very pleased to add Gary to the senior management team at Progyny. He brings a unique mix of knowledge, experience and insight in the fertility and laboratory markets that will help strengthen our growing business. He should make an immediate impact on the company with his vast knowledge base and relationships in the fertility industry.”
Dr. Harton is certified by the American Board of Bioanalysis (ABB) as a Technical Supervisor, Molecular Diagnostics, and is a member of the American Society for Reproductive Medicine (ASRM), European Society of Human Reproduction and Embryology (ESHRE), and Preimplantation Genetic Diagnosis International Society.
Progyny, the combined entity of Auxogyn, Inc. and Fertility Authority LLC, is the first company to provide fertility patients with easy accessibility to high quality doctors, price transparency, and financing, coupled with extraordinary clinical expertise and proprietary clinical solutions. Rooted in clinical excellence and serving as a champion for the consumer, the company is committed to helping ensure that patients control their fertility journey and achieve the best possible outcome. Progyny is privately held and its investors include Kleiner Perkins Caufield & Byers, TPG Biotech, SR One, and Merck Serono Ventures. The company is headquartered in New York, NY with operations in Menlo Park, CA.